Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A new study published in the peer-reviewed OMICS: A Journal of Integrative Biology identified differentially expressed host and viral microRNAs (miRNAs) in six Epstein-Barr virus (EBV) associated tumours.
The study reports several drug candidates for repurposing and targeting EBV latent infection: glyburide, levodopa, nateglinide, and stiripentol, among others.
The authors, Anamika Thakur and Manoj Kumar, PhD, from the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India, note: “This is the first integrative analysis, to the best of our knowledge, in regard to the potential therapeutic targets and drug repurposing candidates against the EBV tumours.”
EBV is associated with several types of malignancies, such as gastric carcinoma, Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin’s lymphoma.
“Epstein-Barr virus is a major planetary health burden especially in the oncology clinic. The study makes a contribution toward antiviral drug innovation for treatment of EBV infection and prevention of EBV-related tumours,” says Vural Özdemir, MD, PhD, DABCP, Editor-in-Chief of OMICS.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.